+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
E

Actively Recruiting

Researchers are evaluating PLN-101095 combined with pembrolizumab in adults with advanced or metastatic solid tumors that have progressed despite prior pembrolizumab treatment. This Phase 1a1b open-label study aims to assess the safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and early signs of antitumor activity of this combination in patients with documented resistance to immune checkpoint inhibitors. The study includes two parts Part 1 involves consecutive dose-escalation cohorts of PLN-101095 at varying doses 250 mg to 2000 mg, administered twice or three times daily combined with pembrolizumab given intravenously every three weeks. Part 2 expands dosing cohorts to evaluate the combination and PLN-101095 monotherapy in specific tumor types, including non-small cell lung cancer, clear cell renal cell carcinoma, and tumor mutational burden-high solid tumors. Participants undergo treatment cycles with regular safety and tumor assessments, including monitoring of side effects and drug levels. Researchers will measure outcomes such as safety and tolerability from first dose through 16 weeks post-treatment, as well as antitumor activity until disease progression or death. The study spans up to several years, with ongoing evaluations to understand the treatments effects and duration of response.

Age: 18Years +All GendersPhase 1
22 locations
S

Actively Recruiting

Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
R

Actively Recruiting

Researchers are evaluating the anti-tumor effects of amivantamab combined with pembrolizumab and carboplatin compared to pembrolizumab, 5-fluorouracil, and platinum therapy in people with recurrent or metastatic head and neck squamous cell carcinoma HNSCC who have not received prior treatment for their advanced cancer. HNSCC affects tissues in the mouth and throat, and this study focuses on treatment-naive participants in this setting. Participants are assigned to one of two groups one receives pembrolizumab, amivantamab, and carboplatin, while the other receives pembrolizumab, 5-fluorouracil given as a 4-day infusion, and either carboplatin or cisplatin. The study compares these treatment combinations to assess their effects on the cancer over a period of up to about 3 years and 7 months. During the study, participants undergo evaluations including imaging scans to measure tumor response using RECIST criteria, blood tests to monitor drug levels and antibodies, and quality of life questionnaires focused on head and neck symptoms and overall health. Researchers track overall survival, tumor response rates, progression-free survival, duration of response, side effects, and symptom changes. The study involves regular visits for treatment and monitoring throughout the treatment and follow-up period.

Age: 18Years +All GendersPhase 3
205 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, preliminary effectiveness, and how the body processes efimosfermin in adults with metabolic dysfunction-associated steatohepatitis MASH and compensated cirrhosis showing stage F4 fibrosis. This study focuses on people diagnosed by liver biopsy with advanced but stable liver disease caused by metabolic problems. It aims to understand the impact of efimosfermin on this condition. Participants will be randomly assigned to one of three groups two groups will receive different doses of efimosfermin, and one group will receive a placebo. All treatments are given as subcutaneous injections once every four weeks. The study will last up to 100 weeks for safety and includes monitoring drug levels in the blood up to 21 weeks. The comparison of two doses of efimosfermin versus placebo allows researchers to assess tolerability and drug behavior. During the trial, participants will be regularly assessed for any treatment-related side effects and have blood samples taken to measure drug concentrations. Researchers will monitor adverse events from the first day through 100 weeks. The study includes multiple visits for injections and evaluations. Participants will be observed closely to gather information on safety and the drugs effects over time, with the total duration extending up to nearly two years.

Age: 18Years - 75YearsAll GendersPhase 2
30 locations
S

Actively Recruiting

Researchers are evaluating Risvutatug rezetecan Ris-Rez, a new medicine targeting specific proteins B7-H3 on cancer cells, in people with relapsed small cell lung cancer SCLC. The study compares Ris-Rez with the standard treatment topotecan to see if Ris-Rez can shrink tumors or make them disappear and if it helps participants live longer. It also examines the safety and side effects of both treatments to better understand their impact. Participants with relapsed SCLC will be randomly assigned to receive either Ris-Rez or topotecan. Both treatments will be administered according to standard protocols, with Ris-Rez provided as a biological therapy and topotecan as a drug treatment. The study is open-label, meaning both participants and researchers know which treatment is given. During the study, participants will be monitored through various assessments including survival time, tumor response, symptom changes, brain progression, and quality of life measures. Safety will be closely tracked through adverse event reports, laboratory tests, heart function evaluations, and immune response monitoring. The main outcome focuses on overall survival, with follow-up extending up to approximately 113 weeks to capture long-term effects and responses.

Age: 18Years +All GendersPhase 3
144 locations
E

Actively Recruiting

Researchers are evaluating a new combination treatment called Risvutatug rezetecan Ris-Rez with ivonescimab for adults who have advanced solid tumors, including certain lung cancers. This early-phase clinical study aims to find out the safe doses, possible side effects, how the body processes these drugs, and which doses might best improve cancer treatment. The study is sponsored by GlaxoSmithKline and involves both Phase 1 and Phase 2 steps. Participants will receive Risvutatug rezetecan and ivonescimab as biological treatments given in a sequential manner. The study includes a dose escalation phase Phase 1 to determine safety and appropriate dosing, followed by a dose expansion phase Phase 2 to further evaluate the treatments effects. Tumor tissue samples are required for participants in the dose expansion phase for biomarker analysis, including the detection of B7 homolog 3 protein expression. Throughout the study, participants will be closely monitored with regular assessments of adverse events, vital signs, body weight, laboratory tests, heart function, and performance status for up to approximately 143 weeks. Researchers will measure treatment safety, dosing effects, objective response rates, disease control, progression-free survival, and overall survival. Blood samples will be collected to study how the drugs behave in the body and to check for immune responses. Participants may remain in the study for long-term follow-up and safety monitoring lasting up to around 169 weeks.

Age: 18Years +All GendersPhase 1Phase 2
4 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
R

Actively Recruiting

Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.

Age: 18Years +All GendersPhase 3
62 locations

1-10 of 21

1